Science Explorer Back to mapMap
Discussion
Institution · CASI Pharmaceuticals (United States)

Most cited papers from CASI Pharmaceuticals (United States)

CASI Pharmaceuticals (United States)

What are the most cited papers from CASI Pharmaceuticals (United States)?

The most cited paper from CASI Pharmaceuticals (United States) is "Requirement for Transcription Factor IRF-1 in NO Synthase Induction in Macrophages" (Ryutaro Kamijo, Hisashi Harada, T. Matsuyama et al., 1994), with 845 citations. Next come "2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF" (732) and "A Systematic Review of Reviews Evaluating Technology-Enabled Diabetes Self-Management Education and Support" (568).

Showing 50 of 60 papers. Every paper with more than 49 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Requirement for Transcription Factor IRF-1 in NO Synthase Induction in Macrophages Ryutaro Kamijo, Hisashi Harada, T. Matsuyama et al. · Science 18 Mar 1994 845
2 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Nicola J. Mabjeesh, Daniel Escuín, Theresa M. LaVallee et al. · Cancer Cell Open access Apr 2003 732
3 A Systematic Review of Reviews Evaluating Technology-Enabled Diabetes Self-Management Education and Support Deborah A. Greenwood, Perry M. Gee, Kathy J. Fatkin et al. · Journal of Diabetes Science and Technology ReviewOpen access 31 May 2017 568
4 Withaferin A is a potent inhibitor of angiogenesis Royce Mohan, Hans J. Hammers, Paola Bargagna‐Mohan et al. · Angiogenesis 2004 383
5 2017 National Standards for Diabetes Self-Management Education and Support Joni K. Beck et al. · Diabetes Care 28 Jul 2017 367
6 Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization and Recovery of Perfusion After Limb Ischemia Marta Bosch‐Marcé, Hiroaki Okuyama, Jacob B. Wesley et al. · Circulation Research Open access 12 Oct 2007 296
7 2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate Victor S. Pribluda, Edward R. Gubish, Edward R. Gubish et al. · Cancer and Metastasis Reviews Review Jun 2000 240
8 Nitric oxide: Cytokine-regulation of nitric oxide in host resistance to intracellular pathogens Shawn J. Green, Libia F. Scheller, Michael A. Marletta et al. · Immunology Letters Dec 1994 238
9 Antiangiogenic Activity of Prostate-Specific Antigen Anne H. Fortier, Barbara J. Nelson, Davida K. Grella et al. · JNCI Journal of the National Cancer Institute Open access 6 Oct 1999 212
10 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Theresa M. LaVallee, Xiaoguo H. Zhan, Chris J Herbstritt et al. · PubMed Jul 2002 206
11 Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Todd Hembrough, Glenn M. Swartz, Adonia E. Papathanassiu et al. · PubMed Jun 2003 197
12 A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. B. Kim Lee Sim, Michael S. O’Reilly, Hong Liang et al. · PubMed Apr 1997 197
13 Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation Elizabeth B. Kelso, John C. Lockhart, Todd Hembrough et al. · Journal of Pharmacology and Experimental Therapeutics 19 Jan 2006 196
14 Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors Matthew H. Kulke, Emily K. Bergsland, David P. Ryan et al. · Journal of Clinical Oncology Open access 28 Jul 2006 174
15 A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer Christopher J. Sweeney, Glenn Liu, Constantin Theodore Yiannoutsos et al. · Clinical Cancer Research 15 Sep 2005 173
16 Hypoglycemia Prediction Using Machine Learning Models for Patients With Type 2 Diabetes Bharath Sudharsan, Malinda Peeples, Mansur E. Shomali · Journal of Diabetes Science and Technology Open access 14 Oct 2014 173
17 Protection ofAotusMonkeys byPlasmodium falciparumEBA‐175 Region II DNA Prime–Protein Boost Immunization Regimen Trevor R. Jones, David L. Narum, Alfonso S. Gozalo et al. · The Journal of Infectious Diseases 15 Jan 2001 144
18 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Theresa M. LaVallee, Xiaoguo H. Zhan, Michelle Smith Johnson et al. · PubMed 15 Jan 2003 142
19 ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action Graham C. Fletcher, Richard D. Brokx, Trisha A. Denny et al. · Molecular Cancer Therapeutics 21 Dec 2010 133
20 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor 1α, Tumor Growth, and Angiogenesis and Augments Paclitaxel Efficacy in Head and Neck Squamous Cell Carcinoma Justin L. Ricker, Zhong Chen, Xin Ping Yang et al. · Clinical Cancer Research 15 Dec 2004 128
21 Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer J S James, Daryl J. Murry, Anthony M. Treston et al. · Investigational New Drugs 13 Sep 2006 128
22 Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies Amye Juliet Tevaarwerk, Kyle D. Holen, Dona B. Alberti et al. · Clinical Cancer Research Open access 15 Feb 2009 124
23 Endostatin Binds Tropomyosin NicholasJ. MacDonald, WandaY. Shivers, David L. Narum et al. · Journal of Biological Chemistry Open access 2001 118
24 Codon Optimization of Gene Fragments Encoding Plasmodium falciparum Merzoite Proteins Enhances DNA Vaccine Protein Expression and Immunogenicity in Mice David L. Narum, Sanjai Kumar, William O. Rogers et al. · Infection and Immunity Open access Dec 2001 117
25 A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC) Michael R. Harrison, Noah M. Hahn, Роберто Пили et al. · Investigational New Drugs Open access 24 May 2010 110
26 The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing Adam C. Berger, Andrew L. Feldman, Michael Gnant et al. · Journal of Surgical Research Jun 2000 107
27 Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Andrew L. Feldman, Lawrence Tamarkin, Giulio F. Paciotti et al. · PubMed Dec 2000 107
28 Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial Daniela Elena Matei, Jeanne M. Schilder, Gregory Patrick Sutton et al. · Gynecologic Oncology 5 Jul 2009 103
29 Molecular Signaling in Bioengineered Tissue Microenvironments Donald Paul Bottaro, Andrea Liebmann-Vinson, Mohammad A. Heidaran · Annals of the New York Academy of Sciences Jun 2002 101
30 Isolation of Murine Macrophages Anne H. Fortier, Lydia A. Falk · Current Protocols in Immunology Sep 1994 101
31 Angiostatin and Endostatin: Endogenous Inhibitors of Tumor Growth B. Kim Lee Sim, Nicholas J. MacDonald, E R Gubish · Cancer and Metastasis Reviews Review Jun 2000 94
32 Evidence-Based mHealth Chronic Disease Mobile App Intervention Design: Development of a Framework Calvin Wilhide, Malinda Peeples, Robin Anthony Kouyaté · JMIR Research Protocols Open access 16 Feb 2016 89
33 A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate Justine Y. Bruce, Jens C. Eickhoff, Роберто Пили et al. · Investigational New Drugs Open access 21 Dec 2010 89
34 Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development Stacy M. Plum · Vaccine Dec 2000 88
35 A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors Matthew H. Kulke, Jennifer Ang Chan, Jeffrey A. Meyerhardt et al. · Cancer Chemotherapy and Pharmacology Open access 19 Oct 2010 86
36 Antibodies against the Plasmodium falciparum Receptor Binding Domain of EBA-175 Block Invasion Pathways That Do Not Involve Sialic Acids David L. Narum, J. David Haynes, Steven R. Fuhrmann et al. · Infection and Immunity Open access Apr 2000 84
37 O‐Mannosylation of Pichia pastoris cellular and recombinant proteins Joseph G. Duman, Robert G. Miele, Hong Yu Liang et al. · Biotechnology and Applied Biochemistry Aug 1998 84
38 Expression and proinflammatory role of proteinase‐activated receptor 2 in rheumatoid synovium: Ex vivo studies using a novel proteinase‐activated receptor 2 antagonist Elizabeth B. Kelso, William R. Ferrell, John C. Lockhart et al. · Arthritis & Rheumatism 27 Feb 2007 84
39 Reduced immunogenicity of DNA vaccine plasmids in mixtures Martha Sedegah, Yupin Charoenvit, Luu Quang Minh et al. · Gene Therapy 19 Feb 2004 83
40 Antitumor Effect of 2-Methoxyestradiol in a Rat Orthotopic Brain Tumor Model Seung-Hee Kang, Heidi T. Cho, Sarojini N. Devi et al. · Cancer Research 15 Dec 2006 82
41 Protein patterns and proteins that identify subtypes of glioblastoma multiforme Makoto Furuta, Robert John Weil, Alexander O. Vortmeyer et al. · Oncogene 2 Aug 2004 81
42 Protection from half‐mustard‐gas‐induced acute lung injury in the rat Shannon D. McClintock, Gerd O. Till, Milton G. Smith et al. · Journal of Applied Toxicology Open access Jul 2002 79
43 Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma S. Vincent Rajkumar, Paul Gerard Guy Richardson, Martha Q. Lacy et al. · Clinical Cancer Research Open access 15 Oct 2007 76
44 Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo Anne H. Fortier, John W. Holaday, Hong Liang et al. · The Prostate 20 May 2003 76
45 Erythrocyte-binding activity of Plasmodium yoelii apical membrane antigen-1 expressed on the surface of transfected COS-7 cells Tresa S. Fraser, Stefan H. I. Kappe, David L. Narum et al. · Molecular and Biochemical Parasitology Sep 2001 75
46 Tissue Factor Pathway Inhibitor Inhibits Endothelial Cell Proliferation via Association with the Very Low Density Lipoprotein Receptor Todd Hembrough, José F. Ruiz, Adonia E. Papathanassiu et al. · Journal of Biological Chemistry Open access Apr 2001 75
47 A novel Plasmodium falciparum erythrocyte binding protein-2 (EBP2/BAEBL) involved in erythrocyte receptor binding David L. Narum, Steven R. Fuhrmann, Tin Luu et al. · Molecular and Biochemical Parasitology Feb 2002 73
48 Co-localization of inducible-nitric oxide synthase and Plasmodium berghei in hepatocytes from rats immunized with irradiated sporozoites. F. Klotz, Libia F. Scheller, Matthew C. Seguin et al. · The Journal of Immunology Apr 1995 73
49 Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University Anupama Kurup, Chih-Ming Lin, Daryl J. Murry et al. · Annals of Oncology Open access 10 Nov 2005 70
50 ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo Christian Moser, Sven Arke Lang, Akira Mori et al. · BMC Cancer Open access 23 Jul 2008 70

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.